Celularity, a clinical-stage cell therapeutics company focused on the development of innovative allogeneic cellular therapies from human placentas, announced pre-clinical data supporting the advancement of CYNK-001, a placental-derived, cryopreserved natural killer (NK) cell therapy, as a clinical candidate for patients with glioblastoma multiforme (GBM).
Results from pre-clinical studies demonstrated in vivo anti-GBM activity of CYNK-001. “The positive results from these pre-clinical studies highlight the versatility and activity of our investigational, off-the-shelf, placental-derived NK cell therapy program,” said Robert Hariri, M.D., Ph.D., Founder, Chairman and CEO at Celularity. “There is a clear need for novel therapeutic approaches to the treatment of glioblastoma multiforme. We look forward to advancing our investigational programs and are optimistic about the possibility of bringing another therapeutic option to patients in need.”